• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.
【24h】

Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.

机译：慢性淋巴细胞性白血病中的抗CD20单克隆抗体。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: The last decade has witnesd immense progress in the treatment of chronic lymphocytic leukemia (CLL). Chemoimmunotherapy (CIT) combining rituximab and fludarabine with cyclophosphamide (FCR) in the frontline setting has clearly been shown to improve outcomes in patients with CLL. Building on the success achieved with rituximab, other anti-CD20 monoclonal antibodies (mAbs) are being investigated. Novel bioengineering techniques have helped in the development of anti-CD20 mAbs. One antibody, ofatumumab, was recently approved for the treatment of refractory CLL. A type II anti-CD20 mAb, GA-101 (obinutuzumab), is currently in clinical trials. This short review focuses on ongoing clinical trials of anti-CD20 mAbs in CLL. AREAS COVERED: Literature search was performed using PubMed ( www.clinicaltrials.gov (till August 2012)), and recent American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), European Hematology association (EHA), International workshop on CLL (iwCLL) abstracts, using the primary search terms 'anti-CD20 monoclonal antibody' with/without CLL. Articles were chosen on the basis of relevance of anti-CD20 mAbs to CLL therapy. EXPERT OPINION: Rituximab, the prototype anti-CD20 mAb, forms the core of CIT in CLL. The success of rituximab and ofatumumab has led investigators to evaluate other anti-CD20 mAbs in the treatment of CLL.
机译：简介：在过去的十年中，慢性淋巴细胞白血病（CLL）的治疗取得了巨大进展。一线治疗中将利妥昔单抗和氟达拉滨与环磷酰胺（FCR）联合使用的化学免疫疗法（CIT）明显改善了CLL患者的预后。在利妥昔单抗取得成功的基础上，正在研究其他抗CD20单克隆抗体（mAb）。新颖的生物工程技术已帮助开发抗CD20单抗。最近批准了一种抗体ofatumumab，用于治疗难治性CLL。 II型抗CD20单抗GA-101（obinutuzumab）目前正在临床试验中。这篇简短的评论重点关注正在进行的CLL中抗CD20 mAb的临床试验。覆盖区域：使用PubMed（www.clinicaltrials.gov（至2012年8月）），最近的美国临床肿瘤学会（ASCO），美国血液学会（ASH），欧洲血液学会（EHA），国际研讨会进行了文献检索使用主要搜索字词“抗CD20单克隆抗体”（带有/不带有CLL）在CLL（iwCLL）摘要上进行检索。根据抗CD20 mAb与CLL治疗的相关性来选择文章。专家意见：利妥昔单抗（原型抗CD20 mAb）构成CLL中CIT的核心。利妥昔单抗和ofatumumab的成功促使研究人员评估了其他抗CD20 mAb在CLL治疗中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号